Neurocrine’s story now hinges on how far its existing medicines can grow and whether its next wave of treatments can reach patients without major setbacks. See what could drive the business forward—and what regulatory, trial, and pricing risks could still derail the outlook.Read more
Neurocrine Biosciences is leaning on growing demand for its leading neurology medicine while pushing for broader insurance coverage to reach more patients. The next leg depends on whether new treatments in its pipeline keep gaining traction before tougher pricing rules and insurer pushback start to bite.Read more
Neurocrine’s growth leans heavily on just a couple of medicines, leaving the business exposed if drug pricing rules tighten, insurers push back, or new rivals take share. At the same time, a broader set of new treatments and improving patient access could keep the story on track—if the pipeline delivers.Read more
Neurocrine’s INGREZZA could reach far more patients as insurance access improves and more people get diagnosed, while new brain and mental health drugs in development may add extra growth engines. But the company still leans heavily on one main product, and shifting rules, payers, and competition could squeeze sales and profits.Read more
No trending discussion available.
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer’s disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
